Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 10, 2015 - Issue
Submit an article Journal homepage
86
Views
11
CrossRef citations to date
0
Altmetric
Original Research

A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study

Georges Juvelekian1 St Georges Hospital University Medical Center, Ashrafieh, Beirut, LebanonCorrespondence[email protected]
,
Waleed El-Sorougi2 Chest Department, Faculty of Medicine, Helwan University, Cairo, Egypt
,
Chaicharn Pothirat3 Division of Pulmonary and Critical Care, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
,
Faisal Yunus4 Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia, Persahabatan Hospital, Jakarta Timur, Indonesia
,
Teresita De Guia5 Department of Pulmonary Medicine, Philippine Heart Center, Quezon City, Philippines
,
Han-Pin Kuo6 Linkou Chang Gun Memorial Hospital, Taoyuan Hsien, Taiwan, ROC
,
Shalma Basu Patnaik7 Novartis Healthcare Pvt Ltd, Rangareddy, Telangana, India
&
Virginia Pilipovic8 Novartis Pharma AG, Basel, Switzerland
 show all
Pages 2109-2120 | Published online: 05 Oct 2015

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Evgenios I. Metaxas & Evangelos Balis. (2018) The safety of indacaterol for the treatment of COPD. Expert Opinion on Drug Safety 17:6, pages 637-642.
Read now

Articles from other publishers (10)

Chihiro Kato, Hajime Yoshisue, Noriko Nakamura & Takayoshi Sasajima. (2022) Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance. Internal Medicine 61:6, pages 789-800.
Crossref
Tomoko Taniguchi, Dong Wang, Hajime Yoshisue, Makoto Nagasaki & Takayoshi Sasajima. (2021) Real-world Safety and Efficacy of Indacaterol Maleate in Patients with Chronic Obstructive Pulmonary Disease: Evidence from the Long-term Post-marketing Surveillance in Japan. Internal Medicine 60:15, pages 2385-2394.
Crossref
David Miller, Soniya Vaidya, Juergen Jauernig, Brian Ethell, Kristina Wagner, Rajkumar Radhakrishnan & Hanns-Christian Tillmann. (2020) Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients. Respiratory Research 21:1.
Crossref
Mauro Contini, Emanuele Spadafora, Simone Barbieri, Paola Gugliandolo, Elisabetta Salvioni, Alessandra Magini, Anna Apostolo, Pietro Palermo, Marina Alimento & Piergiuseppe Agostoni. (2020) Effects of β2-receptor stimulation by indacaterol in chronic heart failure treated with selective or non-selective β-blockers: a randomized trial. Scientific Reports 10:1.
Crossref
Maryam Navaie, Carole Dembek, Soojin Cho-Reyes, Karen Yeh & Bartolome R. Celli. (2020) Inhaler device feature preferences among patients with obstructive lung diseases. Medicine 99:25, pages e20718.
Crossref
Aldo Pezzuto, Marco Stellato, Giovanna Catania, Calogero Mazzara, Sara Tonini, Marco Caricato, Pierfilippo Crucitti & Giuseppe Tonini. (2018) Short-term benefit of smoking cessation along with glycopirronium on lung function and respiratory symptoms in mild COPD patients: a retrospective study. Journal of Breath Research 12:4, pages 046007.
Crossref
Mario Cazzola & Paola Rogliani. (2017) Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. Journal of Comparative Effectiveness Research 6:7, pages 627-636.
Crossref
Pierre-Olivier Girodet, Jean-Yves Jasnot, Vincent Le Gros, Laurent Decuypère, Weihua Cao & Gilles Devouassoux. (2017) Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis. Respiratory Medicine 128, pages 92-101.
Crossref
Ho-Kee YumHak-Ryul KimYoon Soo ChangKyeong-Cheol ShinSong KimYeon-Mok Oh. (2017) Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea. Tuberculosis and Respiratory Diseases 80:1, pages 52.
Crossref
James F. Donohue, Vaidyanathan Ganapathy, Vamsi Bollu, Michael D. Stensland & Lauren M. Nelson. (2017) Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year. Clinical Therapeutics 39:1, pages 66-74.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.